Transdermal drug delivery: Evolving technologies and expanding opportunities

Indian Journal of Pharmaceutical Education and Research

Volumn 43, Issue 3, 2009, Pages 251-259

  Aggarwal, Geeta ^a   Garg, Ashish ^b   Dhawan, Sanju ^c  

^a Rayat Institute of Pharmacy   (India)

^b Eli Lilly Services India Private Limited   (India)

^c PANJAB UNIVERSITY   (India)

Author keywords

Electroporation; Iontophoresis; Microneedle technology; Needleless injections; Pressure waves; Radiofrequency microchannels; Sonophoresis; Transdermal drug delivery

Indexed keywords

ANTIINFLAMMATORY AGENT; DRUG CARRIER; ETHOSOME; FENTANYL; TESTOSTERONE; UNCLASSIFIED DRUG;

BIOENGINEERING; DRUG DELIVERY SYSTEM; ELECTROPORATION; HUMAN; IONTOPHORESIS; MEDICAL TECHNOLOGY; MICRONEEDLE; NEEDLELESS INJECTION; PRESSURE WAVE; RADIOFREQUENCY MICROCHANNEL; REVIEW; TRANSDERMAL DRUG ADMINISTRATION; ULTRASOUND;

EID: 70349122971     PISSN: 00195464     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004;3(2):115-124 (Pubitemid 38239773)
2. Chein YW. Novel drug delivery system: Drugs and Pharmaceutical Sciences. Vol.50. New York: Marcel Dekker Inc; 1992.
3. Gorden RD, Peterson TA. Four myths about transdermal drug delivery. Drug Del Technol 2003;3:1-7.
4. Scheindlin. Transdermal drug delivery: Past, Present, Future. Molecular Interventions 2004;4(6):308-312
5. Kandavilli S, Nair V, Panchagnula R. Polymers in transdermal drug delivery systems. Pharm Technol [serial online] 2002 [cited 2008 jan 15];62-78. Available from: URL: www.pharmtech.com.
6. Rios M. Advances in transdermal technologies: transdermal delivery takes up once forbidden compounds, reviving markets and creating formulation opportunities. Pharm Technol [serial online] 2007 [cited 2008 jan 15];1-5. Available from: URL: www.pharmtech.com.
7. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: Current and future prospects. Drug Deliv 2006;13(3):175-187
8. Meidan VM, Michniak BB. Emerging technologies in transdermal therapeutics. Am J Ther 2004;11:312-316
9. Sivamani RK, Liepmann D, Maibach HI. Microneedles and transdermal applications. Expert Opin Drug Deliv 2007;4:19-25.
10. Henzl MR. Optimizing delivery of therapeutics: percutaneous technologies. Bratisl Lek Listy 2002;103(4-5):144-151
11. Frost and Sullivan. Rise of transdermal drug delivery technologies [online]. 2003 [cited 2008 july 15]. Available from: URL: http://www. Inpharmatechnologist.com/new/ng.asp?id=26435-rise-of-transdermal.
12. Villaneueva Egan LA, Pichardo Cuevas M. Advances in hormonal contraception. Ginecol Obstet Mex 2007;75(1):35-42.
13. Williams AC, Barry BW. Penetration enhancers. Adv Drug Del Rev 2004;56:603-618
14. Karande P, Jain A, Ergun K, Kispersky V, Mitragotri S. Design principles of chemical penetration enhancers for transdermal drug delivery. Proceedings of the national academy of sciences of the USA 2005;102:4688-4693 (Pubitemid 40471515)
15. Banerova K, Matusova D, Kassai Z. Chemical enhancers for transdermal drug transport. Eur J Drug Metab Pharmacokinet 2001;26(1-2):85-94. (Pubitemid 32802400)
16. Touitou E, Dayan N, Bergelson I, Godin B Eliaz M. Ethosomes- Novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. J Control Release 2000;65:403-418 (Pubitemid 30122942)
17. Benson, Heather AE. Transferosomes for transdermal drug delivery. Expert Opin Drug Deliv 2006;3(6):727-737
18. Molokhia SA, Zhang Y, Higuchi WI, Li SK. Iontophoretic transport across a multiple membrane system. J Pharm Sci 2008;97:490-505.
19. Costello CT, Jeske AH. Iontophoresis: applications in transdermal medication delivery. Phys Ther 1995;75:554-563
20. Lopez RFV, Bentley MVLB, Charro MBD, Guy RH. Optimization of aminolevulinic acid (ALA) delivery by iontophoresis. J Control Release 2003;88:65-70.
21. Semalthy A, Semalthy M, Singh R, Saraf SK, Saraf S. Iontophoretic drug delivery system- a review. Technol Health Care 2007;15(4):237-245 (Pubitemid 47219936)
22. Guy Furness. Global overview of the active transdermal drug delivery market [online]. 2007 [cited 2007 sep 20]. Available from: URL: http://www.drugdeliverytech.com/cgibin/articlescgi?idArticle226.
23. Murray AK, Moore TL, King TA, Herrick AL. Vasodilator iontophoresis a possible new therapy for digital ischaemia in systemic sclerosis. Rheumatology (Oxford) 2008;47:76-79
24. Prausnitz MR, Bose VG, Langer R, Weaver JC. Electroporation of mammalian skin: A mechanism to enhance transdermal drug delivery. Proceedings of the National Academy of Sciences of the USA 1993;90:10504-10508 (Pubitemid 23347070)
25. Zaharoff DA, Henshaw JW, Mossop B, Yuan F. Mechanistic analysis of electroporation-induced cellular uptake of macromolecules. Exp Biol Med (Maywood) 2008;233:94-105.
26. Sharma A, Kara M, Smith FR, Krishnan TR. Transdermal drug delivery using electroporation. II. Factors influencing skin reversibiliy in electroporative delivery of terazosin hydrochloride in hairless rats. J Pharm Sci 2000;89(4):536-544 (Pubitemid 30690343)
27. Sen A, Daly ME, Hui SW. Transdermal insulin delivery using lipid enhanced electroporation. Biochim Biophys Acta 2002;1564:5-8. (Pubitemid 34717862)
28. Koch E. FDA approves phase I clinical trials using Ichor's Trigrid system and DNA vaccine for melanoma developed at Sloan Kettering [online]. 2007 [cited 2008 july 18]. Available from: URL: http://www.ichorms.com.
29. Prausnitz MR, Edelman ER, Gimm JA, Langer R, Weaver JC. Transdermal delivery of heparin by skin electroporation. Biotechnology 1995;13:1205-1209
30. Widera G, Austin M, Rabussary D. Increased DNA vaccine delivery and immunogenicity by electroporation in-vitro. J Immunol 2000;164:4635-4640 (Pubitemid 30238062)
31. Medi BM, Hoselton S, Marepalli RB, Singh J. Skin targeted DNA vaccine delivery using electroportation in rabbits- I: Efficacy. Int J Pharm 2005;294(1-2):53-63. (Pubitemid 40462322)
32. Sintov AC. Radiofrequency-driven skin microchanneling as a new way for electrically assisted transdermal delivery of hydrophilic drugs. J Control Release 2003;89:311-320
33. Levin G, Gershonowitz A, Sacks H, Stern M, Sherman A, Rudaev S, et al. Transdermal delivery of Human Growth Hormone through RF-Microchannels. Pharm Res 2005;22(4):550-555 (Pubitemid 40603252)
34. Levin G, Kornfeld J. Crossing the barrier: RF Transdermal drug delivery [online]. 2007 [cited 2007 sep 15]. Available from: URL: http://www.transpharma- medical.com.
35. Merino G, Kalia YN, Guy RH. Ultrasound enhanced transdermal transport. J Pharm Sci 2003;92:1125-1137
36. Sivakumar M, Tachibana K, Pandit AB, Yasui K, Tuziuti K, Towata A, et al. Transdermal drug delivery using ultrasound therapy, understanding and critical analysis. Cell Mol Biol 2005;51:767-784
37. Michael D. Dermisonics' test with Type 2 diabetics proves insulin isn't transported through the skin when patch not activated by ultrasound. Represents another step forward in achieving FDA approval [online]. 2006 [cited 2008 july 18]. Available from: URL: http://www.dermisonics.com.
38. Doukas AG, Kollias N. Transdermal drug delivery with a pressure wave. Adv Drug Deliv Rev 2004;56(5):559-579 (Pubitemid 38326933)
39. Verbaan FJ, Bal SM, Van den Berg DJ, Groenink WHH, Verpoorten H, Luttge R, et al. Assembled microneedle arrays enhance the transport of compounds varying over a large range of molecular weight across human dermatomed skin. J Control Release 2007;117:238-245 (Pubitemid 46161879)
40. Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 2004;56(5):581-587
41. Martano W, Davis SP, Holiday NR, Wang J, Gill HS, Preushitz MR. Transdermal delivery of insulin using microneedles in vivo. Pharm Res 2004;21:947-952 (Pubitemid 38870143)
42. Chandrashekhar NS, Shobha Rani RH. Current status and future prospects in transdermal drug delivery [online]. 2006 [cited 2007 sep 21]. Available from: URL: http://www.pharmainfo.net/pharma-student-magazine.
43. Bremseth DL, Pass F. Delivery of insulin by jet injection: Recent observations. Diabetes Technol Ther 2001;3:225-232 (Pubitemid 32651958)
44. Splinter WM. 'Needle-free' delivery of local anesthesia: a valuable option in pediatrics. Paediatr Drugs 2002;4(6):349-352
45. Burkoth TL, Bellhouse BJ, Hewson G, Longridge DJ, Muddle AJ, Sarphie DJ. Transdermal and transmucosal powdered delivery. Crit Rev Ther Drug Carrier Syst 1999;16:331-384
46. Higo N. Recent trend of transdermal drug delivery system development. Yokugaku Zasshi 2007;127(4):655-662 (Pubitemid 46536538)
47. Ning YM, Rao YF, Liang WQ. Influence of permeation enhancers on transdermal delivery of anemonia. Zhonqquo Zhong Yao Za Zhi 2007;32:393-396
48. Kaplun FW, Toitou E. Testosterone skin permeation enhancement by menthol through formation of eutectic with the drug and interaction with lipid. J Pharm Sci 1997;86:1394-1399
49. Zurdo SI, Franke P, Schaefer UF, Lehr CM. Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs. J Control Release 2007;118:196-203. (Pubitemid 46329735)
50. Budhathoki U, Thapa P. Effect of chemical enhancers on in vitro release of salbutamol sulfate from patches. Kathmandu Univ J Sci Engg Technol 2005;1(1):1-8.
51. Suwanpidokkul N, Thongnopnua P, Umpryan K. Transdermal delivery of zidovudine (AZT): The effects of vehicles, enhancers and polymer membranes on permeation across cadaver pig skin. AAPS PharmSciTech 2004;5:Article 48. (Pubitemid 41086238)
52. Yoneto K, Li SK, Higuchi WI, Shimabaashi S. Influence of the permeation enhancers 1-alkyl-2-pyrrolidones on permeant partitioning into the stratum corneum. J Pharm Sci 1998;87:209-214 (Pubitemid 28081330)
53. Parikh DK, Tapash KG. Feasibility of transdermal delivery of fluoxetine. AAPS PharmSciTech 2005;6(2):E144-9.
54. Mukherjee B, Kanupriya, Mahapatra S, Das S, Patra B. Sorbitan Monolaurate 20 as a potential skin permeation enhancer in transdermal patches. J Appl Res 2005;5(1):96-107. (Pubitemid 40503483)
55. Nokodchi A, Shokri J, Dashbolaghi A, HassanZaheed D, Ghafourian T, Bergeger Jalai M. The enhancement effect of surfactant on penetration of lorazepam through rat skin. Int J Pharm 2003;250(2):359-369 (Pubitemid 36084360)
56. Olivella MS, Lhez L, Pappano NB, Debattista NB. Effects of dimethylformamide and L-menthol permeation enhancers on transdermal delivery of quercetin. Pharm Dev Technol 2007;12:481-484 (Pubitemid 350034882)
57. Jayaaraam B, Bhaskar P. Formulation of an HPMC gel drug reservoir system with ethanol water as a solvent system and limonene as a permeation enhancer for enhancing in vitro transdermal delivery of nicorandil. J Pharmacol Biophysiol Res 2004;17:310-320
58. Kaza R, Pitchaimani R. Formulation of transdermal drug delivery system: Matrix and selection of polymer-their evaluation. Curr Drug Discov Technol 2006;3:279-285 (Pubitemid 46572566)
59. Shin SC, Shin EY, Cho CY. Enhancing effects of fatty acids on piroxicam permeation through rat skins. Drug Dev Ind Pharm 2000;26:563-566
60. Ogiso T, Iwaki M, Paku T. Effect of various penetration enhancers using a novel skin alternative. J Pharm Sci 1995;84:482-488
61. Alvarez-Figueroa MJ, Araya-Silva I, Díaz-Tobar C. Iontophoretic transdermal delivery of haloperidol. Pharm Dev Technol 2006;11(3):371-375
62. Wearley L, Liu JC, Chien YW. Iontophoresis facilitated transdermal delivery of verapamil. 1. In vitro evaluation and mechanistic studies. J Control Release 1989;2:237-250
63. Singh P, Anbinker M, Smith GA, Zavortink D, Maibach HI. Transdermal iontophoresis and solute penetration across excised human skin. J Pharm Sci 1995;84:1342-1346
64. Chandrashekhar G, Bhat R, Singh MK, Udupa N. Optimization of parameters for transdermal permeation of insulin. Indian J Pharm Sci 1994;56:205-209
65. Pacini S, Gulisano M, Punzi T, Ruggiero M. Transdermal delivery of Clostridium botulinum toxin type A by pulsed current iontophoresis. J Am Acad Dermatol 2007;57:1097-1099 (Pubitemid 350087356)
66. Russo J, Lipman A, Lanstock T, Page B, Stephen R. Lidocaine anaesthesia: Comparison of iontophoresis, injection and swabbing. Am J Hosp Pharm 1980;37:843-847 (Pubitemid 11249600)
67. Holovics HJ, Anderson CR, Levine BS, Hui HW, Lunte, CE. Investigation of drug delivery by iontophoresis in a surgical wound utilizing microdialysis. Pharm Res 2007;24(1):1-4.
68. Wallace MS. Topical delivery of lidocaine in healthy volunteers by electroporation, electroincorporation or iontophoresis: an evaluation of skin anaesthesia. Reg Anaesth Pain Med 2001;26:229-238
69. Sen A, Zhao YL, Hui SW. Saturated anionic phospholipids enhance transdermal transport by electroporation. Biophys J 2002;83(4):2064-2073
70. Zewert TE, Pliquett UF, Langer R, Weaver JC. Transdermal transport of DNA antisense oligonucleotides by electroporation. Biochim Biophys Res Com 1995;212:286-292
71. Zang L, Lerner S, Rustrum WV, Hofmann GA. Electroporation mediated topical delivery of vitamin C for cosmetic applications. Bioelectrochem Bioenerget 1999;48:453-461 (Pubitemid 29225182)
72. Tachibana K. Transdermal delivery of insulin to alloxan diabetic rabbits by ultrasound exposure. Pharm Res 1992;9:952-954
73. Mitragotri S, Kost J. Transdermal delivery of heparin and low molecular weight heparin using low frequency ultrasound. Pharm Res 2001;18:1151-1156 (Pubitemid 32900401)
74. Terahara T, Mitragotri S, Langer R. Porous resins as cavitation enhancer for low frequency sonophoresis. J Pharm Sci 2002;91:753-759 (Pubitemid 34639638)
75. Nordquist L, Roxhed N, Griss P, Stemme G. Novel microneedle patches for active insulin delivery are efficient in maintaining glycaemic control: an initial comparison with subcutaneous administration. Pharm Res 2007;24:1381-1388 (Pubitemid 46870597)
76. McAllister DV, Allen MG Prausitz MR. Microfabricated microneedles for gene and drug delivery. Annu Rev Biomed Eng 2000;2:289-313.